MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)

May 26, 2026 updated by: Pfizer

A PHASE 3, OPEN-LABEL STUDY OF ELRANATAMAB MONOTHERAPY VERSUS ELOTUZUMAB, POMALIDOMIDE, DEXAMETHASONE (EPd) OR POMALIDOMIDE, BORTEZOMIB, DEXAMETHASONE (PVd) OR CARFILZOMIB, DEXAMETHASONE (Kd) IN PARTICIPANTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA WHO RECEIVED PRIOR ANTI-CD38 DIRECTED THERAPY

The purpose of this study is to learn about the study medicine called elranatamab.This study aims to compare elranatamab to other medicines for the treatment of MM (a type of cancer).

This study is seeking participants who:

Are 18 years of age or older and have MM.
Have received treatments before for MM.
Have MM that has returned or not responded to their most recent treatment.

Half of the participants will receive elranatamab. The other half of participants will receive a combination therapy selected by the study doctor. The selected combination therapy will include 2 to 3 different medicines commonly used to treat MM.

Elranatamab will be given as a shot under the skin at the study clinic about once a week. This may change to a smaller number of shots later in the study.

The medicines in the combination therapy will be taken by mouth (at home or at the study clinic) AND will be given either as:

a shot under the skin at the study clinic
through a needle in the vein at the study clinic The number of times these medicines will be taken depends on what combination therapy the study doctor selects.

Participants may continue to receive elranatamab or a combination therapy until their MM is no longer responding. The study team will see how each participant is doing with the study treatment during regular visits at the study clinic. The study team will continue to follow-up with participants after study treatment with telephone contacts (or visits).

The study will compare the experiences of people receiving elranatamab to those people receiving a combination therapy. This will help learn about the safety and how effective elranatamab is.

Study Overview

Status

Recruiting

Conditions

Multiple Myeloma

Intervention / Treatment

Study Type

Interventional

Enrollment (Estimated)

492

Phase

Phase 3

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Name: Pfizer CT.gov Call Center
Phone Number: 1-800-718-1021
Email: ClinicalTrials.gov_Inquiries@pfizer.com

Study Locations

Argentina
- - La Plata, Argentina, 1900
    - Recruiting
    - Hospital Italiano de La Plata
- Buenos Aires
  - Ciudad Autónoma de Buenos Aires, Buenos Aires, Argentina, C1426ANZ
    - Recruiting
    - Instituto Alexander Fleming
  - Pilar, Buenos Aires, Argentina, 1629
    - Recruiting
    - Hospital Universitario Austral
- Buenos Aires F.D.
  - Ciudad de Buenos Aires, Buenos Aires F.D., Argentina, C1199ABB
    - Recruiting
    - Hospital Italiano de Buenos Aires
Australia
- New South Wales
  - Blacktown, New South Wales, Australia, 2148
    - Recruiting
    - Blacktown Hospital
  - Concord, New South Wales, Australia, 2139
    - Recruiting
    - Concord Repatriation General Hospital
- Queensland
  - Birtinya, Queensland, Australia, 4575
    - Recruiting
    - Sunshine Coast University Hospital
  - Brisbane, Queensland, Australia, 4029
    - Recruiting
    - Royal Brisbane and Women's Hospital
- Victoria
  - Fitzroy, Victoria, Australia, 3065
    - Recruiting
    - St Vincent's Hospital (Melbourne)
  - Geelong, Victoria, Australia, 3220
    - Recruiting
    - Barwon Health
- Western Australia
  - Nedlands, Western Australia, Australia, 6009
    - Recruiting
    - Sir Charles Gairdner Hospital, Haematology Clinical Trials
Belgium
- Brabant Wallon
  - Ottignies, Brabant Wallon, Belgium, 1340
    - Recruiting
    - Clinique Saint Pierre
- Bruxelles-capitale, Région de
  - Brussels, Bruxelles-capitale, Région de, Belgium, 1090
    - Recruiting
    - UZ Brussel
- Hainaut
  - Gilly, Hainaut, Belgium, 6060
    - Recruiting
    - Grand Hopital De Charleroi
  - Hornu, Hainaut, Belgium, 7301
    - Recruiting
    - Centre Hospitalier Epicura
- Liège
  - Verviers, Liège, Belgium, 4800
    - Recruiting
    - CHR Verviers - La Tourelle
- Namur
  - Yvoir, Namur, Belgium, 5530
    - Recruiting
    - Université Catholique de Louvain-Namur - Centre Hospitalier Universitaire Dinant-Godinne - Site Godi
- West-vlaanderen
  - Roeselare, West-vlaanderen, Belgium, 8800
    - Recruiting
    - AZ Delta vzw
Brazil
- - Rio de Janeiro, Brazil, 22793-080
    - Recruiting
    - Instituto de Educação, Pesquisa e Gestão em Saúde
  - Rio de Janeiro, Brazil, 20775-001
    - Recruiting
    - Instituto de Educação, Pesquisa e Gestão em Saúde
  - Rio de Janeiro, Brazil, 22775001
    - Recruiting
    - Americas Centro de Oncologia Integrado
  - São Paulo, Brazil, 01232-010
    - Recruiting
    - ESHO Empresa de Serviços Hospitalares S.A/ Hospital Samaritano de Higienópolis
  - São Paulo, Brazil, 04537-080
    - Recruiting
    - Clínica Médica São Germano S/S Ltda
  - São Paulo, Brazil, 04024-002
    - Recruiting
    - Universidade Federal de Sao Paulo
  - São Paulo, Brazil, 04024-002
    - Recruiting
    - HU UNIFESP / SPDM - Hospital São Paulo
  - São Paulo, Brazil, 01401-002
    - Recruiting
    - Instituto D'Or de Pesquisa e Ensino (IDOR)
  - São Paulo, Brazil, 04004-030
    - Active, not recruiting
    - Hospital do Coracao
  - São Paulo, Brazil, 04086-011
    - Active, not recruiting
    - INSUMA
- Estado de Bahia
  - Salvador, Estado de Bahia, Brazil, 41253-190
    - Recruiting
    - Instituto D'Or de Pesquisa e Ensino (IDOR) - Filial Salvador
- Rio Grande do Sul
  - Porto Alegre, Rio Grande do Sul, Brazil, 90110-270
    - Recruiting
    - Centro Gaucho Integrado De Oncologia, Hematologia, Ensino E Pesquisa
  - Porto Alegre, Rio Grande do Sul, Brazil, 90850-170
    - Recruiting
    - Centro de Pesquisa Clínica - Área Administrativa
  - Porto Alegre, Rio Grande do Sul, Brazil, 90880-480
    - Recruiting
    - Hospital Mae de Deus
  - Porto Alegre, Rio Grande do Sul, Brazil, 90035-001
    - Recruiting
    - Hospital Moinhos de Vento
- Rio de Janeiro
  - Niterói, Rio de Janeiro, Brazil, 24220-070
    - Recruiting
    - Instituto Oncomed de Educação e Pesquisa
  - Niterói, Rio de Janeiro, Brazil, 24220-300
    - Recruiting
    - Oncomed Clínica Oncológica
- São Paulo
  - Jaú, São Paulo, Brazil, 17210-080
    - Recruiting
    - Hospital Amaral Carvalho
  - Ribeirão Preto, São Paulo, Brazil, 14051-140
    - Recruiting
    - Hospital das Clínicas da Faculdade de Medicina de Ribeirão Preto da Universidade de São Paulo (USP)
  - SP, São Paulo, Brazil, 04537-080
    - Recruiting
    - Clínica Médica São Germano LTDA
  - São Paulo, São Paulo, Brazil, 04543-000
    - Recruiting
    - Instituto D'Or de Pesquisa e Ensino (IDOR)
Canada
- New Brunswick
  - Moncton, New Brunswick, Canada, E1C 6Z8
    - Recruiting
    - The Moncton Hospital
- Quebec
  - Montreal, Quebec, Canada, H3T 1E2
    - Recruiting
    - Jewish General Hospital
  - Montreal, Quebec, Canada, H4J 1C5
    - Recruiting
    - Centre intégré universitaire de santé et de services sociaux du Nord-de-l'Île-de-Montréal (CIUSSS NÎ
Chile
- Santiago Metropolitan
  - Santiago, Santiago Metropolitan, Chile, 7580206
    - Recruiting
    - Clínica Inmunocel
  - Santiago, Santiago Metropolitan, Chile, 7500921
    - Recruiting
    - FALP
  - Santiago, Santiago Metropolitan, Chile, 7620157
    - Recruiting
    - Clinica Universidad de Los Andes
  - Santiago, Santiago Metropolitan, Chile, 7650568
    - Recruiting
    - Clínica Alemana de Santiago
Croatia
- - Osijek, Croatia, 31000
    - Not yet recruiting
    - Klinički bolnički centar Osijek
  - Rijeka, Croatia, 51000
    - Recruiting
    - Klinicki Bolnicki Centar Rijeka
  - Split, Croatia, 21 000
    - Recruiting
    - Klinički Bolnički Centar Split
  - Zagreb, Croatia, 10000
    - Recruiting
    - Klinicka bolnica Dubrava
  - Zagreb, Croatia, 10 000
    - Not yet recruiting
    - Sestre milosrdnice University Hospital Center
  - Zagreb, Croatia, 10000
    - Recruiting
    - Klinicka bolnica Merkur
  - Zagreb, Croatia, 10 000
    - Recruiting
    - University Hospital Center Zagreb
Czechia
- - Prague, Czechia, 100 34
    - Recruiting
    - Fakultní Nemocnice Královské Vinohrady
- Brno-město
  - Brno, Brno-město, Czechia, 625 00
    - Recruiting
    - Fakultní nemocnice Brno Bohunice
- Praha 10
  - Prague, Praha 10, Czechia, 100 34
    - Recruiting
    - Fakultní Nemocnice Královské Vinohrady
Denmark
- - Copenhagen Ø, Denmark, DK 2100
    - Recruiting
    - Rigshospitalet
- Central Jutland
  - Aarhus, Central Jutland, Denmark, 8200
    - Recruiting
    - Aarhus Universitetshospital, Skejby
- North Denmark
  - Aalborg, North Denmark, Denmark, 9000
    - Recruiting
    - Aalborg Universitetshospital, Syd
Finland
- - Oulu, Finland, 90220
    - Active, not recruiting
    - Oulun yliopistollinen sairaala
- Southwest Finland
  - Turku, Southwest Finland, Finland, 20520
    - Active, not recruiting
    - Turku University Hospital
- Uusimaa
  - Helsinki, Uusimaa, Finland, 00029
    - Active, not recruiting
    - Helsinki University Hospital - Comprehensive Cancer Center (HYKS - Syöpäkeskus)
France
- - Bayonne, France, 64109
    - Recruiting
    - Centre Hospitalier de La Côte Basque
  - La Roche-sur-Yon, France, 85925
    - Recruiting
    - CHD Vendee
  - Le Mans, France, 72037
    - Recruiting
    - Centre Hospitalier du Mans
  - Paris, France, 75015
    - Recruiting
    - Hôpital Universitaire Necker Enfants Malades
  - Paris, France, 75679
    - Recruiting
    - Hopitaux Universitaires Paris Centre-Hopital Cochin
  - Quimper, France, 29107
    - Recruiting
    - Centre Hospitalier de Cornouaille
  - Tours, France, 37044
    - Recruiting
    - Centre Hospitalier Regional Universitaire de Tours - Hopital Bretonneau
  - Vannes, France, 56000
    - Active, not recruiting
    - Centre Hospitalier Bretagne Atlantique
  - Vannes, France, 56017
    - Active, not recruiting
    - Centre Hospitalier Bretagne Atlantique
- Aquitaine
  - Pessac, Aquitaine, France, 33600
    - Recruiting
    - CHU Bordeaux Haut-Leveque
- Haute-garonne
  - Toulouse, Haute-garonne, France, 31100
    - Recruiting
    - Institut Universitaire du Cancer Toulouse - Oncopole - CHU de TOULOUSE
- Hauts-de-France
  - Dunkirk, Hauts-de-France, France, 59385
    - Active, not recruiting
    - Centre Hospitalier de Dunkerque
- Lorraine
  - Vandœuvre-lès-Nancy, Lorraine, France, 54511
    - Active, not recruiting
    - Centre Hospitalier Régional Universitaire de Nancy - Hôpitaux de Brabois
- Pays de la Loire Region
  - Nantes, Pays de la Loire Region, France, 44000
    - Recruiting
    - Centre Hospitalier Universitaire de Nantes - L' Hopital l'hôtel-Dieu
- Val-d'oise
  - Pontoise, Val-d'oise, France, 95300
    - Recruiting
    - Hôpital NOVO
- Val-de-marne
  - Créteil, Val-de-marne, France, 94010
    - Recruiting
    - Henri Mondor Hospital
- Vienne
  - City/Town/Village, Vienne, France, 86021
    - Recruiting
    - Centre Hospitalier Universitaire De Poitiers
Germany
- - Berlin, Germany, 10967
    - Recruiting
    - Vivantes Klinikum am Urban
  - Berlin, Germany, 10249
    - Recruiting
    - Vivantes Klinikum am Urban
  - Cottbus, Germany, 03048
    - Recruiting
    - Medizinische Universität Lausitz - Carl Thiem
  - Hamburg, Germany, 22763
    - Recruiting
    - Asklepios Altona
  - Hamm, Germany, 59073
    - Recruiting
    - St. Barbara-Klinik Hamm-Heessen
  - Speyer, Germany, 67346
    - Recruiting
    - Diakonissen-Stiftungs-Krankenhaus Speyer
- Baden-Wurttemberg
  - Freiburg im Breisgau, Baden-Wurttemberg, Germany, 79106
    - Recruiting
    - Universitaetsklinikum Freiburg
  - Stuttgart, Baden-Wurttemberg, Germany, 70376
    - Recruiting
    - Robert Bosch Krankenhaus GmbH
  - Ulm, Baden-Wurttemberg, Germany, 89081
    - Recruiting
    - Universitaetsklinikum Ulm
- Bavaria
  - Nuremberg, Bavaria, Germany, 90419
    - Recruiting
    - Klinikum Nürnberg Nord
- North Rhine-Westphalia
  - Bonn, North Rhine-Westphalia, Germany, 53127
    - Recruiting
    - Universitätsklinikum Bonn
- Thuringia
  - Jena, Thuringia, Germany, 07747
    - Recruiting
    - Universitatsklinikum Jena
Greece
- Anatolikí Makedonía KAI Thráki
  - Alexandroupoli, Anatolikí Makedonía KAI Thráki, Greece, 681 00
    - Active, not recruiting
    - University General Hospital Of Alexandroupoli
- Attikí
  - Athens, Attikí, Greece, 115 28
    - Active, not recruiting
    - Alexandra General Hospital of Athens
- Kentrikí Makedonía
  - Thessaloniki, Kentrikí Makedonía, Greece, 54639
    - Active, not recruiting
    - "Theagenio" Cancer Hospital of Thessaloniki
- Thessaloníki
  - Thessaloniki, Thessaloníki, Greece, 570 10
    - Active, not recruiting
    - G. Papanikolaou General Hospital
- Ípeiros
  - Ioannina, Ípeiros, Greece, 455 00
    - Active, not recruiting
    - University Hospital of Ioannina
Israel
- Central District
  - Petah Tikva, Central District, Israel, 4910021
    - Recruiting
    - Rabin Medical Center
  - Ramat Gan, Central District, Israel, 5265601
    - Recruiting
    - Sheba Medical Center
- Jerusalem
  - Jerusalem, Jerusalem, Israel, 9112001
    - Recruiting
    - Hadassah Medical Center
- Southern District
  - Beersheba, Southern District, Israel, 8410101
    - Recruiting
    - Soroka Medical Center
- TELL ABĪB
  - Tel Aviv, TELL ABĪB, Israel, 6423906
    - Recruiting
    - Sourasky Medical Center
Italy
- - Bologna, Italy, 40138
    - Active, not recruiting
    - IRCCS Azienda Ospedaliero-Universitaria di Bologna, Policlinico di Sant'Orsola
  - Meldola (FC), Italy, 47014
    - Active, not recruiting
    - IRCCS - Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori"
  - Milan, Italy, 20141
    - Active, not recruiting
    - Istituto Europeo di Oncologia IRCCS
  - Milan, Italy, 20142
    - Recruiting
    - ASST Santi Paolo e Carlo Ospedale San Paolo
  - Pescara, Italy, 65124
    - Recruiting
    - Ospedale Civile dello Spirito Santo
- Lombardy
  - Milan, Lombardy, Italy, 20153
    - Recruiting
    - P.O. San Carlo Borromeo- ASST SANTI PAOLO E CARLO
- Milano
  - Legnano, Milano, Italy, 20025
    - Active, not recruiting
    - Azienda Socio Sanitaria Ovest milanese
- Piedmont
  - Turin, Piedmont, Italy, 10126
    - Active, not recruiting
    - Azienda Ospedaliero-Universitaria Città della Salute e della Scienza di Torino
- Sicily
  - Palermo, Sicily, Italy, 90127
    - Active, not recruiting
    - A.O.U. Policlinico Paolo Giaccone
- The Marches
  - Ancona, The Marches, Italy, 60126
    - Recruiting
    - Azienda Ospedaliero Universitaria delle Marche
- Tuscany
  - Florence, Tuscany, Italy, 50134
    - Active, not recruiting
    - Azienda Ospedaliera Universitaria Careggi
  - Pisa, Tuscany, Italy, 56126
    - Active, not recruiting
    - Azienda Ospedaliero Universitaria Pisana
Japan
- - Kagoshima, Japan, 890-8520
    - Recruiting
    - Kagoshima University Hospital
  - Kyoto, Japan, 602-8566
    - Recruiting
    - University Hospital,Kyoto Prefectural University of Medicine
  - Okayama, Japan, 701-1192
    - Recruiting
    - National Hospital Organization Okayama Medical Center
  - Okayama, Japan, 702-8055
    - Not yet recruiting
    - Okayama Rosai Hospital
  - Yamagata, Japan, 990-9585
    - Recruiting
    - Yamagata University Hospital
- Aichi-ken
  - Toyohashi, Aichi-ken, Japan, 441-8570
    - Recruiting
    - Toyohashi Municipal Hospital
- Ehime
  - Matsuyama, Ehime, Japan, 790-0024
    - Recruiting
    - Ehime Prefectural Central Hospital
- Gifu
  - Ōgaki, Gifu, Japan, 503-8502
    - Active, not recruiting
    - Ogaki Municipal Hospital
- Gunma
  - Maebashi, Gunma, Japan, 371-8511
    - Recruiting
    - Gunma University Hospital
  - Shibukawa, Gunma, Japan, 377-0280
    - Recruiting
    - National Hospital Organization Shibukawa Medical Center
- Hyōgo
  - Kobe, Hyōgo, Japan, 650-0047
    - Recruiting
    - Kobe City Medical Center General Hospital
- Iwate
  - Shiwa-gun Yahaba-cho, Iwate, Japan, 028-3695
    - Recruiting
    - Iwate Medical University Hospital
- Shizuoka
  - Nagaizumi-cho, Shizuoka, Japan, 411-8777
    - Active, not recruiting
    - Shizuoka Cancer Center
- Tokyo
  - Bunkyo-ku, Tokyo, Japan, 113-8603
    - Recruiting
    - Nippon Medical School Hospital
  - Koto, Tokyo, Japan, 135-8550
    - Recruiting
    - Japanese Foundation for Cancer Research
  - Koto, Tokyo, Japan, 135-8550
    - Recruiting
    - The Cancer Institute Hospital of JFCR
- Yamanashi
  - Kofu, Yamanashi, Japan, 400-8506
    - Recruiting
    - Yamanashi Prefectural Central Hospital
Netherlands
- Limburg
  - Maastricht, Limburg, Netherlands, 6229 HX
    - Recruiting
    - Maastricht UMC+
- South Holland
  - Dordrecht, South Holland, Netherlands, 3318 AT
    - Recruiting
    - Albert Schweitzer Ziekenhuis, locatie Dordwijk
  - Rotterdam, South Holland, Netherlands, 3015 GD
    - Recruiting
    - Erasmus Medisch Centrum
Norway
- - Oslo, Norway, 0450
    - Recruiting
    - Oslo Universitetssykehus Ullevål
- Akershus
  - Lørenskog, Akershus, Norway, 1478
    - Recruiting
    - Akershus Universitetssykehus
- Sør-trøndelag
  - Trondheim, Sør-trøndelag, Norway, 7030
    - Recruiting
    - St. Olavs Hospital
- Vestfold
  - Tønsberg, Vestfold, Norway, 3103
    - Recruiting
    - Sykehuset I Vestfold
Portugal
- - Braga, Portugal, 4710-243
    - Active, not recruiting
    - 2Ca Braga
- Lisbon District
  - Lisbon, Lisbon District, Portugal, 1099-023
    - Active, not recruiting
    - Instituto Portugues de Oncologia de Lisboa Francisco Gentil
Slovakia
- - Bratislava, Slovakia, 833 10
    - Active, not recruiting
    - Narodny Onkologicky Ustav
  - Bratislava, Slovakia, 851 07
    - Active, not recruiting
    - Univerzitna nemocnica Bratislava, Nemocnica sv. Cyrila a Metoda
- Banská Bystrica Region
  - Banská Bystrica, Banská Bystrica Region, Slovakia, 97517
    - Active, not recruiting
    - Fakultna nemocnica s poliklinikou F.D.Roosevelta Banska Bystrica
- Košice Region
  - Košice, Košice Region, Slovakia, 040 11
    - Active, not recruiting
    - Univerzitna nemocnica L. Pasteura Kosice
Slovenia
- - Ljubljana, Slovenia, 1000
    - Not yet recruiting
    - University Medical Centre Ljubljana
South Korea
- Seoul-teukbyeolsi [seoul]
  - Seoul, Seoul-teukbyeolsi [seoul], South Korea, 03080
    - Recruiting
    - Seoul National University Hospital
  - Seoul, Seoul-teukbyeolsi [seoul], South Korea, 06351
    - Recruiting
    - Samsung Medical Center
  - Seoul, Seoul-teukbyeolsi [seoul], South Korea, 03722
    - Recruiting
    - Severance Hospital, Yonsei University Health System
Spain
- - Madrid, Spain, 28007
    - Active, not recruiting
    - Hospital General Universitario Gregorio Marañon
  - Madrid, Spain, 28050
    - Active, not recruiting
    - Hospital Universitario HM Sanchinarro
  - Málaga, Spain, 29010
    - Active, not recruiting
    - H.R.U Málaga - Hospital General
  - Salamanca, Spain, 37007
    - Active, not recruiting
    - Hospital Universitario de Salamanca - Complejo Asistencial Universitario de Salamanca
  - Valencia, Spain, 46026
    - Active, not recruiting
    - Hospital Universitari i Politecnic La Fe
- Barcelona [barcelona]
  - Badalona, Barcelona [barcelona], Spain, 08916
    - Active, not recruiting
    - Institut Català d'Oncologia (ICO) - Badalona
  - Terrassa, Barcelona [barcelona], Spain, 08221
    - Active, not recruiting
    - Hospital Universitari Mutua Terrassa
- Basque Country
  - Barakaldo, Basque Country, Spain, 48903
    - Active, not recruiting
    - OSI Ezkerraldea-Enkarterri-Cruces - Hospital Universitario Cruces
- Catalunya [cataluña]
  - Barcelona, Catalunya [cataluña], Spain, 08036
    - Active, not recruiting
    - Hospital Clínic de Barcelona
- Galicia [galicia]
  - Murcia, Galicia [galicia], Spain, 30008
    - Active, not recruiting
    - Hospital General Universitario Morales Meseguer
- Girona [gerona]
  - Girona, Girona [gerona], Spain, 17007
    - Active, not recruiting
    - Institut Català d'Oncologia (ICO) - Girona
- Valenciana, Comunitat
  - Valencia, Valenciana, Comunitat, Spain, 46004
    - Active, not recruiting
    - ASCIRES ECG Médica S.L
Sweden
- - Falun, Sweden, 791 31
    - Active, not recruiting
    - Falu Lasarett
- Örebro LÄN [se-18]
  - Örebro, Örebro LÄN [se-18], Sweden, 701 85
    - Active, not recruiting
    - Universitetssjukhuset Örebro
Taiwan
- - Taichung, Taiwan, 407
    - Recruiting
    - Taichung Veterans General Hospital
  - Taichung, Taiwan, 404332
    - Recruiting
    - China Medical University Hospital
United Kingdom
- - Canterbury, United Kingdom, CT1 3NG
    - Recruiting
    - Kent and Canterbury Hospital
  - Wolverhampton, United Kingdom, WV10 0QP
    - Recruiting
    - New Cross Hospital
- Buckinghamshire
  - Milton Keynes, Buckinghamshire, United Kingdom, MK6 5LD
    - Recruiting
    - Milton Keynes Hospital
- Denbighshire [SIR Ddinbych Gb-ddb]
  - Bodelwyddan, Denbighshire [SIR Ddinbych Gb-ddb], United Kingdom, LL18 5UJ
    - Recruiting
    - Glan Clwyd Hospital
- Dorset
  - Bournemouth, Dorset, United Kingdom, BH7 7DW
    - Recruiting
    - Royal Bournemouth Hospital
  - Poole, Dorset, United Kingdom, BH15 2JB
    - Recruiting
    - Poole Hospital
- EAST Sussex
  - Eastbourne, EAST Sussex, United Kingdom, BN21 2UD
    - Recruiting
    - Eastbourne District General Hospital
  - Worthing, EAST Sussex, United Kingdom, BN11 2DH
    - Recruiting
    - Worthing Hospital
- England
  - Birmingham, England, United Kingdom, B15 2TH
    - Recruiting
    - Queen Elizabeth Hospital Birmingham
- Greater London
  - London, Greater London, United Kingdom, E1 1BB
    - Recruiting
    - Barts Health NHS Trust
- Gwynedd
  - Bangor, Gwynedd, United Kingdom, LL57 2PW
    - Recruiting
    - Betsi Cadwaladr University Health Board
- KENT
  - Maidstone, KENT, United Kingdom, ME16 9QQ
    - Recruiting
    - Maidstone Hospital
- London, CITY of
  - London, London, CITY of, United Kingdom, EC1A 7BE
    - Recruiting
    - St Bartholomew'S Hospital
  - London, London, CITY of, United Kingdom, SE1 9RT
    - Recruiting
    - Guy's & St Thomas' NHS Foundation Trust
  - London, London, CITY of, United Kingdom, SE5 9RL
    - Recruiting
    - King's College Hospital
- Oxfordshire
  - Oxford, Oxfordshire, United Kingdom, OX3 7LE
    - Recruiting
    - Churchill Hospital
- Staffordshire
  - Stoke-on-Trent, Staffordshire, United Kingdom, ST4 6QG
    - Recruiting
    - Royal Stoke University Hospital
- Sutton
  - London, Sutton, United Kingdom, SM2 5PT
    - Recruiting
    - Royal Marsden Hospital (Sutton)
United States
- Alabama
  - Mobile, Alabama, United States, 36607
    - Recruiting
    - Infirmary Cancer Care
- Arizona
  - Goodyear, Arizona, United States, 85338
    - Recruiting
    - Western Regional Medical Center, Inc. dba. City of Hope Phoenix
- California
  - Beverly Hills, California, United States, 90211
    - Recruiting
    - Beverly Hills Cancer Center
  - Clovis, California, United States, 93611
    - Recruiting
    - Community Cancer Institute
  - Clovis, California, United States, 93611
    - Recruiting
    - Clovis Community Medical Center
  - Encino, California, United States, 91316
    - Recruiting
    - Clinical Research Advisors (Encino Satellite Location)
  - Fresno, California, United States, 93701
    - Recruiting
    - University of California San Francisco
  - Fresno, California, United States, 93721
    - Recruiting
    - Community Regional Medical Center
  - Irvine, California, United States, 92618
    - Recruiting
    - Hoag Hospital Irvine
  - Irvine, California, United States, 92618
    - Recruiting
    - Hoag Health Center Irvine
  - Los Angeles, California, United States, 90067
    - Recruiting
    - Valkyrie Clinical Trials
  - Los Angeles, California, United States, 90020
    - Recruiting
    - Clinical Research Advisors (Korea Town Satellite Location)
  - Los Angeles, California, United States, 90048
    - Recruiting
    - Clinical Research Advisors (West Hollywood Satellite Location)
  - Newport Beach, California, United States, 92663
    - Recruiting
    - Hoag Memorial Hospital Presbyterian
  - Panorama City, California, United States, 91402
    - Recruiting
    - Mission Community Hospital (Satellite Site)
  - Sacramento, California, United States, 95817
    - Recruiting
    - University of California Davis (UC Davis) Comprehensive Cancer Center
  - Sacramento, California, United States, 95817
    - Recruiting
    - University of California
- Colorado
  - Fort Collins, Colorado, United States, 80524
    - Recruiting
    - UCHealth Poudre Valley Hospital
  - Fort Collins, Colorado, United States, 80528
    - Recruiting
    - UCHealth Harmony
  - Greeley, Colorado, United States, 80634
    - Recruiting
    - UCHealth Greeley Hospital
  - Longmont, Colorado, United States, 80504
    - Recruiting
    - UCHealth Longs Peak Hospital
  - Longmont, Colorado, United States, 80504
    - Recruiting
    - UCHealth Longs Peak Medical Center
  - Loveland, Colorado, United States, 80538
    - Recruiting
    - UCHealth - Medical Center of the Rockies
- Florida
  - Coral Gables, Florida, United States, 33146
    - Not yet recruiting
    - Sylvester Comprehensive Cancer Center - The Lennar Foundation Medical Center
  - Deerfield Beach, Florida, United States, 33442
    - Not yet recruiting
    - University of Miami Hospital and Clinics - Deerfield Beach
  - Doral, Florida, United States, 33166
    - Not yet recruiting
    - Sylvester Comprehensive Cancer Center- Doral
  - Hollywood, Florida, United States, 33021
    - Not yet recruiting
    - Sylvester Comprehensive Cancer Center - Hollywood
  - Miami, Florida, United States, 33176
    - Recruiting
    - Baptist Hospital of Miami
  - Miami, Florida, United States, 33176
    - Recruiting
    - Miami Cancer Institute at Baptist Health, Inc.
  - Miami, Florida, United States, 33136
    - Not yet recruiting
    - Sylvester Comprehensive Cancer Center
  - Miami, Florida, United States, 33136
    - Not yet recruiting
    - University of Miami Hospital and Clinics
  - Miami, Florida, United States, 33136
    - Not yet recruiting
    - University of Miami Hospital and Clinics - Griffin Cancer Research Building
  - Miami, Florida, United States, 33176
    - Not yet recruiting
    - Sylvester Comprehensive Cancer Center- Kendall
  - Plantation, Florida, United States, 33322
    - Recruiting
    - BRCR Global
  - Plantation, Florida, United States, 33322
    - Recruiting
    - BRCR Medical Center Inc
  - Tamarac, Florida, United States, 33321
    - Recruiting
    - BRCR Global - Tamarac
- Illinois
  - Chicago, Illinois, United States, 60625
    - Recruiting
    - Endeavor Health - Swedish Hospital
  - Evanston, Illinois, United States, 60201
    - Recruiting
    - Endeavor Health - Evanston Hospital
  - Glenview, Illinois, United States, 60026
    - Recruiting
    - Endeavor Health - Glenbrook Hospital Ambulatory Care Center
  - Highland Park, Illinois, United States, 60035
    - Recruiting
    - Endeavor Health - Highland Park Hospital Health Center 1
  - Springfield, Illinois, United States, 62781
    - Recruiting
    - Springfield Memorial Hospital
  - Springfield, Illinois, United States, 62702
    - Recruiting
    - Simmons Cancer Institute at SIU
  - Springfield, Illinois, United States, 62703
    - Recruiting
    - Springfield Clinic Main Campus
  - Springfield, Illinois, United States, 62769
    - Recruiting
    - HSHS St. John's Hospital
  - Zion, Illinois, United States, 60099
    - Recruiting
    - Midwestern Regional Medical Center, Inc. dba City of Hope Chicago
- Indiana
  - Indianapolis, Indiana, United States, 46250
    - Recruiting
    - Community Health Network, Inc.
  - Indianapolis, Indiana, United States, 46227
    - Recruiting
    - Community Health Network, Inc.
  - Indianapolis, Indiana, United States, 46256
    - Recruiting
    - Community Health Network, Inc.
- Kansas
  - Kansas City, Kansas, United States, 66112
    - Recruiting
    - American Oncology Partners, P.A. Dba MidAmerica Cancer Care
  - Leawood, Kansas, United States, 66211
    - Recruiting
    - Ascentist Doctors' Hospital
  - Merriam, Kansas, United States, 66204
    - Recruiting
    - American Oncology Partners, P.A. Dba MidAmerica Cancer Care
- Massachusetts
  - Boston, Massachusetts, United States, 02215
    - Recruiting
    - Beth Israel Deaconess Medical Center
  - Boston, Massachusetts, United States, 02215
    - Recruiting
    - BIDMC Research Pharmacy
- Missouri
  - Belton, Missouri, United States, 64012
    - Recruiting
    - American Oncology Partners, P.A. Dba MidAmerica Cancer Care
  - Independence, Missouri, United States, 64057
    - Recruiting
    - MIVA Medical
  - Kansas City, Missouri, United States, 64128
    - Not yet recruiting
    - Kansas City VA Medical Center
  - Kansas City, Missouri, United States, 64132
    - Recruiting
    - American Oncology Partners, P.A. Dba MidAmerica Cancer Care
- Nebraska
  - Lincoln, Nebraska, United States, 68506
    - Recruiting
    - Bryan Medical Center
  - Lincoln, Nebraska, United States, 68506
    - Recruiting
    - NHO Revive Research Institute, LLC
- New Jersey
  - Morristown, New Jersey, United States, 07960
    - Recruiting
    - Atlantic Health System Morristown Medical Center
- New York
  - Hawthorne, New York, United States, 10532
    - Active, not recruiting
    - WMCHealth Advanced Physician Services
  - Lake Success, New York, United States, 11042
    - Recruiting
    - Northwell Health/ RJ Zuckerberg Cancer Center
  - Manhasset, New York, United States, 11030
    - Recruiting
    - North Shore University Hospital
  - New Hyde Park, New York, United States, 11040
    - Recruiting
    - Long Island Jewish Medical Center
  - Valhalla, New York, United States, 10595
    - Active, not recruiting
    - Westchester Medical Center
- North Carolina
  - Greenville, North Carolina, United States, 27834
    - Recruiting
    - Brody School of Medicine at East Carolina University
  - Greenville, North Carolina, United States, 27834
    - Recruiting
    - ECU Health Medical Center
- North Dakota
  - Fargo, North Dakota, United States, 58102
    - Recruiting
    - Sanford Fargo Medical Center
- Ohio
  - Cincinnati, Ohio, United States, 45236
    - Recruiting
    - The Jewish Hospital
  - Cincinnati, Ohio, United States, 45245
    - Recruiting
    - Oncology Hematology Care Clinical Trials, Llc
  - Cincinnati, Ohio, United States, 45220
    - Recruiting
    - TriHealth Cancer Institute-Good Samaritan Hospital
  - Cincinnati, Ohio, United States, 45242
    - Recruiting
    - Oncology Hematology Care Clinical Trials, Llc
  - Cincinnati, Ohio, United States, 45242
    - Recruiting
    - TriHealth Cancer Institute- Thomas Comprehensive Care Center
  - Cincinnati, Ohio, United States, 45211
    - Recruiting
    - Oncology Hematology Care Clinical Trials, Llc
  - Cincinnati, Ohio, United States, 45236
    - Recruiting
    - Oncology Hematology Care Clinical Trials, Llc
  - Cleveland, Ohio, United States, 44195
    - Recruiting
    - Cleveland Clinic
- Pennsylvania
  - Pittsburgh, Pennsylvania, United States, 15224
    - Recruiting
    - AHN West Penn Hospital
- Rhode Island
  - Providence, Rhode Island, United States, 02906
    - Recruiting
    - The Miriam Hospital
  - Providence, Rhode Island, United States, 02903
    - Recruiting
    - Brown University Health Cancer Institute
- South Carolina
  - Greenville, South Carolina, United States, 29607
    - Active, not recruiting
    - St Francis Cancer Center
- Tennessee
  - Nashville, Tennessee, United States, 37203
    - Recruiting
    - Ascension St. Thomas Hospital
  - Nashville, Tennessee, United States, 37203
    - Recruiting
    - Tennessee Oncology, PLLC - Investigational Drug Services
  - Nashville, Tennessee, United States, 37203
    - Recruiting
    - Tennessee Oncology, PLLC - Nashville Elliston Place Plaza Center for Blood Cancers
  - Nashville, Tennessee, United States, 37203
    - Recruiting
    - Tennessee Oncology, PLLC - Nashville Elliston Place Plaza DDU
  - Nashville, Tennessee, United States, 37203
    - Recruiting
    - Tennessee Oncology, PLLC - Nashville Elliston Place Plaza Medical Oncology & Hematology
- Texas
  - Dallas, Texas, United States, 75246
    - Recruiting
    - Baylor University Medical Center
  - Dallas, Texas, United States, 75246
    - Recruiting
    - Baylor University Medical Center, Investigational Drug Services, Department of Pharmacy
  - Houston, Texas, United States, 77070
    - Recruiting
    - Houston Methodist Willowbrook Hospital
  - Houston, Texas, United States, 77030
    - Recruiting
    - Houston Methodist Hospital Cancer Center
  - Houston, Texas, United States, 77030
    - Recruiting
    - Houston Methodist Cancer Center Infusion
  - Houston, Texas, United States, 77030
    - Recruiting
    - Houston Methodist Hospital - Department of Pharmacy
  - Lubbock, Texas, United States, 79410
    - Recruiting
    - Joe Arrington Cancer Research and Treatment Center
  - Sugar Land, Texas, United States, 77479
    - Recruiting
    - Houston Methodist Sugar Land Hospital
  - Temple, Texas, United States, 76508
    - Recruiting
    - Baylor Scott & White Medical Center - Temple
- West Virginia
  - Morgantown, West Virginia, United States, 26506
    - Recruiting
    - WVU Cancer Institute
- Wisconsin
  - Madison, Wisconsin, United States, 53718
    - Recruiting
    - University of Wisconsin Carbone Cancer Center - Eastpark Medical Center
  - Madison, Wisconsin, United States, 53792
    - Recruiting
    - University of Wisconsin Carbone Cancer Center-University Hospital

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

Adult
Older Adult

Accepts Healthy Volunteers

Description

Inclusion Criteria:

Prior diagnosis of multiple myeloma as defined by International Myeloma Working Group (IMWG) criteria and previously received 1 to 4 prior lines of therapy including prior anti-cluster of differentiation 38 (CD38) antibody and prior lenalidomide.
Documented evidence of progressive disease or failure to achieve a response to last line of therapy per IMWG criteria.
Measurable disease defined as at least 1 of the following: (a) Serum M-protein ≥0.5 g/dL; (b) Urinary M-protein excretion ≥200 mg/24 hours; (c) Serum involved immunoglobulin FLC ≥10 mg/dL AND abnormal serum immunoglobulin kappa to lambda FLC ratio (<0.26 or >1.65).
Have clinical laboratory values within the specified range.
ECOG (Eastern Cooperative Oncology Group) performance status ≤2.
Not pregnant or breastfeeding and willing to use contraception.

Exclusion Criteria:

Smoldering multiple myeloma.
Plasma cell leukemia.
Amyloidosis.
Polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy and skin abnormalities (POEMS) syndrome.
Known central nervous system (CNS) involvement or clinical signs of myelomatous meningeal involvement.
Stem cell transplant within 12 weeks prior to enrolment, or active graft versus host disease.
Any active, uncontrolled bacterial, fungal, or viral infection.
Any other active malignancy within 3 years prior to enrolment (exceptions include, adequately treated basal cell or squamous cell skin cancer, carcinoma in situ)
Previous treatment with a B cell maturation antigen (BCMA)-directed therapy or CD3-redirecting therapy.
Unable to receive investigator's choice therapy.
Live attenuated vaccine within 4 weeks of the first dose of study intervention.
Administration with an investigational product (e.g. drug or vaccine) within 30 days preceding the first dose of study intervention used in this study.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Interventional Model: Parallel Assignment
Masking: None (Open Label)

Number of Arms

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Elranatamab Participants will receive elranatamab monotherapy	Drug: Elranatamab Elranatamab will be administered subcutaneously
Active Comparator: Investigator's Choice Participants will receive either Elotuzumab, Pomalidomide and Dexamethasone (EPd), or Pomalidomide, Bortezomib and Dexamethasone (PVd), or Carfilzomib and Dexamethasone (Kd)	Drug: Elotuzumab Elotuzumab will be administered intravenously Drug: Pomalidomide Pomalidomide will be administered orally Drug: Dexamethasone Dexamethasone will be administered orally Drug: Bortezomib Bortezomib will be administered subcutaneously or intravenously Drug: Carfilzomib Carfilzomib will be administered intravenously

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Progression free survival per International Myeloma Working Group criteria Time Frame: Up to approximately 5 years	From date of randomization to date of progressive disease, discontinuation from study, death, or censoring, whichever occurs first	Up to approximately 5 years

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Overall survival Time Frame: Up to approximately 5 years	From date of randomization to date of discontinuation from study, death, or censoring, whichever occurs first	Up to approximately 5 years
Progression free survival on next-line treatment per International Myeloma Working Group criteria Time Frame: Up to approximately 5 years	From date of randomization to date of second objective disease progression, discontinuation from the study, death, or censoring, whichever occurs first	Up to approximately 5 years
Objective response rate per International Myeloma Working Group criteria Time Frame: Up to approximately 5 years	From date of randomization to date of progressive disease, discontinuation from study, death, or start of new anticancer therapy	Up to approximately 5 years
Duration of response per International Myeloma Working Group criteria Time Frame: Up to approximately 5 years	From date of confirmed objective response to date of progressive disease, discontinuation from study, death, or censoring, whichever occurs first	Up to approximately 5 years
Very good partial response or better response rate per International Myeloma Working Group criteria Time Frame: Up to approximately 5 years	From date of randomization to date of progressive disease, discontinuation from study, death, or start of new anticancer therapy, whichever occurs first	Up to approximately 5 years
Complete response rate per International Myeloma Working Group criteria Time Frame: Up to approximately 5 years	From date of randomization to date of progressive disease, discontinuation from study, death, or start of new anticancer therapy, whichever occurs first	Up to approximately 5 years
Duration of complete response per International Myeloma Working Group criteria Time Frame: Up to approximately 5 years	From date of confirmed complete response to date of progressive disease, discontinuation from study, death, or censoring, whichever occurs first	Up to approximately 5 years
Time to response per International Myeloma Working Group criteria Time Frame: Up to approximately 5 years	From date of randomization to date of confirmed objective response	Up to approximately 5 years
Minimal residual disease negativity rate per International Myeloma Working Group criteria Time Frame: Up to approximately 5 years	From date of randomization to date of progressive disease, discontinuation from study, death, or start of new anticancer therapy, whichever occurs first	Up to approximately 5 years
Sustained minimal residual disease negativity rate per International Myeloma Working Group criteria Time Frame: Up to approximately 5 years	From date of randomization to date of progressive disease, discontinuation from study, death, or start of new anticancer therapy, whichever occurs first	Up to approximately 5 years
Duration of minimal residual disease negativity rate per International Myeloma Working Group criteria Time Frame: Up to approximately 5 years	From date of minimal residual disease negativity to date of relapse, death, or censoring, whichever occurs first	Up to approximately 5 years
Frequency of treatment-emergent adverse events Time Frame: From date of first dose of study intervention up to 90 days after last study intervention administration		From date of first dose of study intervention up to 90 days after last study intervention administration
Frequency of abnormal laboratory results Time Frame: From date of first dose of study intervention up to 90 days after last study intervention administration		From date of first dose of study intervention up to 90 days after last study intervention administration
Free elranatamab serum trough concentration [Ctrough] Time Frame: From date of first dose of elranatamab up to approximately 14 days after last dose of elranatamab		From date of first dose of elranatamab up to approximately 14 days after last dose of elranatamab
Elranatamab immunogenicity by anti-drug antibodies against elranatamab Time Frame: From date of first dose of elranatamab up to approximately 14 days after last dose of elranatamab		From date of first dose of elranatamab up to approximately 14 days after last dose of elranatamab
Health-related quality of life by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire - Core 30 Time Frame: From date of informed consent up to approximately 35 days after last administration of study intervention	Change from baseline scores	From date of informed consent up to approximately 35 days after last administration of study intervention
Health-related quality of life by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire - Myeloma 20 Time Frame: From date of informed consent up to approximately 35 days after last administration of study intervention	Change from baseline scores	From date of informed consent up to approximately 35 days after last administration of study intervention

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Pfizer

Investigators

Study Director: Pfizer CT.gov Call Center, Pfizer

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Helpful Links

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

February 8, 2024

Primary Completion (Estimated)

August 30, 2026

Study Completion (Estimated)

December 30, 2027

Study Registration Dates

First Submitted

November 17, 2023

First Submitted That Met QC Criteria

November 28, 2023

First Posted (Actual)

November 30, 2023

Study Record Updates

Last Update Posted (Actual)

May 28, 2026

Last Update Submitted That Met QC Criteria

May 26, 2026

Last Verified

May 1, 2026

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

C1071032
2023-507871-23-00 (Registry Identifier: CTIS (EU))
MAGNETISMM-32 (Other Identifier: Alias Study Number)

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

YES

IPD Plan Description

Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

Yes

Studies a U.S. FDA-regulated device product

product manufactured in and exported from the U.S.

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Multiple Myeloma

Zhongshan Hospital (Xiamen), Fudan University

Not yet recruiting

Exploratory Clinical Trial of DQ1001 in Relapsed or Refractory Multiple Myeloma (RRMM)

Multiple Myeloma Progression | Multiple Myeloma Refractory
University Health Network, Toronto

Not yet recruiting

Study of the Safety and Usefulness of Liposomal Curcumin in Multiple Myeloma

Multiple Myeloma in Relapse | Multiple Myeloma Refractory

Canada
Lawson Health Research Institute
The Ottawa Hospital; Hamilton Health Sciences Corporation; Dalhousie University; Niagara Health System

Active, not recruiting

Rivaroxaban or Aspirin As Thromboprophylaxis in Multiple Myeloma (RithMM)

Multiple Myeloma in Relapse | Multiple Myeloma With Failed Remission | Multiple Myeloma Stage I | Multiple Myeloma Progression | Multiple Myeloma Stage II | Multiple Myeloma Stage III

Canada
Second Affiliated Hospital, School of Medicine,...
Tongji Hospital; Jinhua Municipal Central Hospital; Taizhou Hospital of Zhejiang...

Recruiting

Novel CD19/BCMA Dual-Targeted CAR-T Cell Therapy for the Treatment of Relapsed/Refractory Multiple Myeloma

Relapse Multiple Myeloma

China
Guangzhou Bio-gene Technology Co., Ltd

Withdrawn

BCMA/GPRC5D CAR-T Therapy for Multiple Myeloma

Multiple Myeloma Refractory
Fred Hutchinson Cancer Research Center/University...
National Cancer Institute (NCI)

Completed

Vaccine Therapy in Treating Patients With Multiple Myeloma Who Have Undergone Stem Cell Transplantation

Stage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple Myeloma

United States
Case Comprehensive Cancer Center
National Cancer Institute (NCI)

Terminated

Lenalidomide After Donor Stem Cell Transplant and Bortezomib in Treating Patients With High Risk Multiple Myeloma

Stage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple Myeloma

United States
Mayo Clinic

Completed

Plerixafor in Treating Patients With Multiple Myeloma Previously Treated With Lenalidomide and Planning to Undergo Autologous Stem Cell Transplant

Multiple Myeloma | Stage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple Myeloma

United States
National Cancer Institute (NCI)

Terminated

Obatoclax and Bortezomib in Treating Patients With Relapsed or Refractory Multiple Myeloma

Stage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple Myeloma

United States
National Cancer Institute (NCI)

Completed

Sunitinib in Treating Patients With Relapsed Multiple Myeloma

Stage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple Myeloma

United States

Clinical Trials on Elranatamab

M.D. Anderson Cancer Center
Pfizer

Recruiting

A Phase 2 Study of Radiotherapy-induced Immune Priming to Enhance Elranatamab (Elra) in Relapsed Refractory Multiple Myeloma (RRMM) With Extramedullary Disease (EMD) and Paramedullary Disease (PMD) "PRIME-EMD-PMD"

Elranatamab | PMD | Relapsed Refractory Multiple Myeloma (RRMM) | Extramedullary Disease in Multiple Myeloma | Phase 2 | Radiotherapy-Induced Immune Priming | Paramedullary Disease

United States
H. Lee Moffitt Cancer Center and Research Institute
Pfizer

Recruiting

Elranatamab Post Cilta-cel in Patients With Clinical High Risk Relapsed Myeloma

Myeloma

United States
Pfizer
In Expanded Access, treating physicians are the Sponsors

No longer available

Pre-approval Single-patient Expanded Access for Elranatamab (PF-06863135)

Multiple Myeloma
University of California, San Diego

Recruiting

Elranatamab in Relapsed/Refractory Multiple Myeloma

Multiple Myeloma

United States
Brigham and Women's Hospital

Recruiting

Elranatamab in Patients With Relapsed or Refractory AL Amyloidosis

AL Amyloidosis

United States
Peking University People's Hospital
Pfizer

Not yet recruiting

ASPIRE: A Registry Study Of Chinese Patients With TCE-RRMM Treated By Elranatamab (ASPIRE)

TCE-RRMM

China
Stichting European Myeloma Network
Pfizer

Recruiting

Use of Elranatamab in Patients With High-risk Smoldering Multiple Myeloma (ERASMM)

Smoldering Multiple Myeloma

Netherlands, France, Italy, Greece, Finland, Norway
Case Comprehensive Cancer Center

Not yet recruiting

Dose Schedule Study of BCMA Bispecific Antibody, Elranatamab, for Newly Diagnosed Immunoglobulin Light Chain (AL) Amyloidosis

Amyloid Light-chain Amyloidosis

United States
Thomas Lund
Pfizer; Vejle Hospital

Recruiting

Self-administration of Subcutaneous Elranatamab in the Patients' Homes. (ERICA)

Multiple Myeloma

Denmark
Pfizer

Recruiting

Elranatamab Post Trial Access Study for Participants With Multiple Myeloma (MM) (MagnetisMM15)

Multiple Myeloma

Canada, United States, Taiwan, China, Japan, Australia

MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)

A PHASE 3, OPEN-LABEL STUDY OF ELRANATAMAB MONOTHERAPY VERSUS ELOTUZUMAB, POMALIDOMIDE, DEXAMETHASONE (EPd) OR POMALIDOMIDE, BORTEZOMIB, DEXAMETHASONE (PVd) OR CARFILZOMIB, DEXAMETHASONE (Kd) IN PARTICIPANTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA WHO RECEIVED PRIOR ANTI-CD38 DIRECTED THERAPY

Study Overview

Status

Conditions

Intervention / Treatment

Study Type

Enrollment (Estimated)

Phase

Contacts and Locations

Study Contact

Study Locations

Participation Criteria

Eligibility Criteria

Ages Eligible for Study

Accepts Healthy Volunteers

Description

Study Plan

How is the study designed?

Design Details

Number of Arms

Arms and Interventions

Participant Group / Arm

Intervention / Treatment

What is the study measuring?

Primary Outcome Measures

Outcome Measure

Measure Description

Time Frame

Secondary Outcome Measures

Outcome Measure

Measure Description

Time Frame

Collaborators and Investigators

Sponsor

Investigators

Publications and helpful links

Helpful Links

Study record dates

Study Major Dates

Study Start (Actual)

Primary Completion (Estimated)

Study Completion (Estimated)

Study Registration Dates

First Submitted

First Submitted That Met QC Criteria

First Posted (Actual)

Study Record Updates

Last Update Posted (Actual)

Last Update Submitted That Met QC Criteria

Last Verified

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

IPD Plan Description

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

Studies a U.S. FDA-regulated device product

product manufactured in and exported from the U.S.

Clinical Trials on Multiple Myeloma

Clinical Trials on Elranatamab

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Slovakia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations